Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy postmenopausal women age 50 years or older~* At least three lumbar vertebrae (L1-L4) must be evaluable by dual energy x-ray absorptiometry (DXA) for bone mineral densitometry that is, without fracture or significant degenerative disease, as determined by the central imaging facility~* Have osteoporosis defined as: Either a T-score of ≤ -2.5 at the lumbar spine, femoral neck, or total hip, AND a T-score of at least \< -1.0 at the lumbar spine; or A T-score of ≤ -2.0 at the lumbar spine, femoral neck, or total hip, AND at least one vertebral fracture;~Exclusion Criteria:~* Active hepatitis;~* Active pancreatitis;~* Unstable cardiac disease;~* Unstable pulmonary disease;~* Celiac disease;~* Hyper- or hypo-parathyroidism;~* Hyperthyroidism;~* Cushing's disease;~* Osteomalacia;~* Paget's disease;~* Osteogenesis imperfecta;~* Known blood disorders;~* History of kidney stones;~* Impaired renal function;~* Autoimmune diseases;~* Bone metastases or a history of skeletal malignancies;~* Cancer history that includes any cancer within the previous 5 years, with the exception of squamous or basal cell carcinoma of the skin in which the lesions were fully resected with clear margins described in a written report by a pathologist, and the patient has had no recurrence of lesions for at least 1 year from the time of original resection;~* Any condition or disease that may interfere with the ability to have or the evaluation of a DXA scan, for example, severe osteoarthritis of the spine, spinal fusion, pedicle screws, history of vertebroplasty, or degenerative disease that results in insufficient number of evaluable lumbar vertebrae, or \>1 lumbar vertebral fracture in L1-L4;~* More than 4 vertebral fractures in T4-L4;~* Bilateral hip replacements;~* Use of fluoride (e.g. fluoride therapy for osteoporosis) or strontium at any time;~* Have received methotrexate or immunomodulatory agents with antiproliferative activity;~* With known dermatological disorders that would interfere with the study procedures or assessments, or with a history of contact dermatitis;~* With known allergy or sensitivity to tapes, adhesives, PTH, teriparatide or its analogs, or components of the Macroflux® systems;~* Who, in the opinion of the investigator, should not participate in the study, or may not be capable of following the study schedule for any reason; and~* Unwillingness or inability to abide by the requirements of the study.~* Have received any intravenous (IV) administered bisphosphonates in the past 24 months, or \>2 doses of IV administered bisphosphonates total;~* Use of oral bisphosphonates before randomization, including investigational bisphosphonates, unless: \<6 months of treatment and off for 6 months, or 6-12 months of treatment and off for 2 years, or \>12 months of treatment and off for 5 years;

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macroflux® placebo (Type: PLACEBO_COMPARATOR): Macroflux® placebo patch
- Macroflux® 20 mcg (Type: EXPERIMENTAL): Macroflux® 20 mcg patch
- Macroflux® 30 mcg (Type: EXPERIMENTAL): Macroflux® 30 mcg patch
- Macroflux® 40 mcg (Type: EXPERIMENTAL): Macroflux® 40 mcg patch
- FORTEO® (Type: ACTIVE_COMPARATOR): FORTEO® 20 mcg injection

Based on this trial design, predict the completion outcome and termination type (if applicable).